Entrada Therapeutics Reports Third Quarter 2026 Financial Results

Lower quarterly research spending helped narrow the loss, while nine-month net loss increased from the prior-year period.

Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) reported a third-quarter 2026 net loss of $39.7 million while advancing its Duchenne muscular dystrophy trials. The loss narrowed from $44.1 million a year earlier; collaboration revenue fell to $0.9 million from $1.6 million. Cash, cash equivalents and marketable securities totaled $193.0 million at September 30, down from $295.7 million at year-end 2025. Entrada expects funding to last into the fourth quarter of 2027.

ELEVATE-44-201 Cohort 1 completed open-label dosing, with data expected by year-end 2026 and Cohort 2 results expected in early 2027. ELEVATE-45-201 Cohort 1 met its safety and tolerability objectives, although one participant had two serious adverse events that resolved. Entrada expects Cohort 2 data in the first half of 2027. ENTR-601-45 received FDA orphan drug designation, and Vertex expects GALILEO interim results in the second half of 2026.

21 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 13 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointThird-quarter net loss narrowed to $39.742 million from $44.134 million a year earlier.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Expected cash runway extended into Q4 2027, based on current operating plans.
• Minor pointThird-quarter loss per share narrowed to $0.94 from $1.06 a year earlier.
• Minor pointThird-quarter research and development expenses fell to $32.369 million from $38.361 million a year earlier.
• Minor pointThird-quarter administrative expenses fell to $10.225 million from $10.304 million a year earlier.

16 minor points

• Minor pointNine-month research and development expenses fell to $100.792 million from $108.312 million a year earlier.
• Minor pointNine-month administrative expenses fell to $30.841 million from $31.500 million a year earlier.
• Minor point. Forward-looking: it has not happened yet and may not happen.ELEVATE-44-201 Cohort 1 completed open-label dosing; 6 mg/kg cohort data are expected by year-end 2026.
• Minor pointELEVATE-44-201 Cohort 1 previously met safety and tolerability objectives, without discontinuations or serious adverse events.
• Minor point. Forward-looking: it has not happened yet and may not happen.ELEVATE-44-201 Cohort 2 enrollment completed at 12 mg/kg; dosing continues, with data expected in Q1 2027.
• Minor pointELEVATE-44-201 Cohort 3 enrollment is ongoing at 18 mg/kg following an independent monitoring committee recommendation.
• Minor pointELEVATE-45-201 Cohort 1 met safety and tolerability objectives at 5 mg/kg, with no discontinuations.
• Minor pointELEVATE-45-201 Cohort 1 showed no hypomagnesemia or renal safety concerns; secondary objectives met company expectations.
• Minor pointELEVATE-45-201 Cohort 1 participants entered the open-label Phase 2 portion, receiving six doses of 5 mg/kg.
• Minor point. Forward-looking: it has not happened yet and may not happen.ELEVATE-45-201 Cohort 2 enrollment completed at 10 mg/kg; dosing continues, with data expected in H1 2027.
• Minor pointENTR-601-45 received FDA orphan drug designation for Duchenne muscular dystrophy in October 2026.
• Minor point. Forward-looking: it has not happened yet and may not happen.Long-term extension protocol accepted by U.K. and European authorities supports continued treatment and longer-term data collection.
• Minor point. Forward-looking: it has not happened yet and may not happen.Vertex completed GALILEO multiple-dose enrollment and dosing; interim results expected in H2 2026.
• Minor pointEntrada named ocular candidate ENTR-801 for potential Usher syndrome type 2A treatment.
• Minor point. Forward-looking: it has not happened yet and may not happen.Entrada plans to nominate a second ocular clinical candidate by year-end 2026.
• Minor pointTotal liabilities declined to $68.555 million at September 30, 2026, from $71.245 million at year-end 2025.

Negative

• Moderate pointCash and securities fell to $193.015 million from $295.698 million at year-end 2025, primarily funding operations.
• Moderate pointNine-month collaboration revenue declined to $2.678 million from $24.122 million a year earlier.
• Moderate pointNine-month net loss widened to $122.222 million from $104.586 million a year earlier.
• Minor pointThird-quarter collaboration revenue declined to $0.905 million from $1.614 million a year earlier.
• Minor pointNine-month loss per share widened to $2.90 from $2.53 a year earlier.

8 minor points

• Minor pointThird-quarter interest and other income fell to $1.974 million from $3.571 million a year earlier.
• Minor pointNine-month interest and other income fell to $6.833 million from $11.936 million a year earlier.
• Minor pointELEVATE-45-201 Cohort 1 included two serious adverse events in one participant: vomiting and pyrexia, both resolved.
• Minor point. Forward-looking: it has not happened yet and may not happen.ELEVATE-45-201 Cohort 3 initiation at up to 15 mg/kg depends on independent review of Cohort 2 safety.
• Minor point. Forward-looking: it has not happened yet and may not happen.ELEVATE-44-102 design and timing remain dependent on lead-program data review and further FDA engagement.
• Minor point. Forward-looking: it has not happened yet and may not happen.Additional ELEVATE-50-201 and ENTR-601-51 applications await lead-program data review; execution strategy is being finalized.
• Minor pointTotal assets declined to $266.880 million at September 30, 2026, from $377.378 million at year-end 2025.
• Minor pointStockholders’ equity declined to $198.325 million at September 30, 2026, from $306.133 million at year-end 2025.

News Explained

Entrada reports that enrollment is ongoing in ELEVATE-44-201 Cohort 3 at the planned 18 mg/kg dose, after an independent safety committee recommended initiating the cohort.

Key Figures

Cash and marketable securities: $193.0 million Cash runway: Into Q4 2027 R&D expenses: $32.4 million +5 more

Cash and marketable securities

$193.0 million

As of September 30, 2026; compared with $295.7 million at December 31, 2025

Cash runway

Into Q4 2027

Based on current operating plans and September 30, 2026 cash position

R&D expenses

$32.4 million

Q3 2026; compared with $38.4 million in Q3 2025

Net loss

$39.7 million

Q3 2026; compared with $44.1 million in Q3 2025

ELEVATE-45-201 Cohort 1 dose

5 mg/kg

Cohort 1 met its primary objectives of favorable safety and tolerability

ELEVATE-44-201 Cohort 1 data

By year-end 2026

Open-label period data expected

ELEVATE-44-201 Cohort 2 data

Q1 2027

Company on track to report data

ELEVATE-45-201 Cohort 2 data

H1 2027

Enrollment complete; dosing ongoing

Previous Earnings Reports

1 past event · Latest: Aug 05

Same Type 1 event

1. Aug 05

   Quarterly earnings

   24h Move

   -2.5%

   Reported $223.0 million cash and runway into Q3 2027; the current report states runway into Q4 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

multiple ascending dose, pharmacokinetic, pharmacodynamic, exon skipping, +1 more

5 terms

multiple ascending dose medical

"participants in the multiple ascending dose (MAD) period"

A multiple ascending dose is a method used in testing new medicines where small groups of people receive gradually larger amounts of the drug over time. This approach helps researchers find the safest and most effective dose without causing too many side effects. For investors, it signals ongoing steps in drug development that can impact a company's potential success or approval prospects.

pharmacokinetic medical

"review of safety, pharmacokinetic and pharmacodynamic data"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

pharmacodynamic medical

"review of safety, pharmacokinetic and pharmacodynamic data"

Pharmacodynamic describes how a drug acts on the body — the biological effects it produces, how strong those effects are, and how long they last. For investors, pharmacodynamic data show whether a treatment actually works and at what dose, shaping expectations about a drug’s safety, effectiveness, regulatory success and market potential; think of it like testing how well a key turns a lock and whether it reliably opens the door.

exon skipping medical

"relationship between dose, exon skipping, dystrophin production and functional outcomes"

A laboratory method that alters how a cell reads a gene so it ignores (or “skips”) a faulty segment, allowing the rest of the gene to produce a shorter but working version of a protein. Think of it like skipping a damaged chapter in a manual so the appliance can still function. Investors care because exon skipping is a targeted drug approach that can create new therapies, influence clinical trial outcomes, regulatory decisions, and future revenue potential.

orphan drug designation regulatory

"granted orphan drug designation for ENTR-601-45"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

-- All ELEVATE-44-201 Cohort 1 participants have completed open-label dosing, with data expected to be received by year-end 2026 --

-- Company on track to report ELEVATE-44-201 Cohort 2 data in Q1 2027 –

-- ELEVATE-45-201 Cohort 1 data reported in October 2026 met the primary objective of favorable safety and tolerability at an initial dose of 5 mg/kg --

-- ELEVATE-45-201 Cohort 2 enrollment complete and Company on track to report data in H1 2027 --

-- Expected cash runway extended into Q4 2027 with $193 million in cash, cash equivalents and marketable securities as of September 30, 2026 --

BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the third quarter ended September 30, 2026, and highlighted recent business updates.

“The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics. “With these initial dose cohorts supporting the safety profile of our lead Duchenne programs, our attention now turns to the next set of readouts designed to further define the potential of our investigational medicines. We expect the ELEVATE-44-201 Cohort 1 open-label data to provide important insights into the underlying biology and the durability of the early functional improvements observed to date. The ELEVATE-44-201 Cohort 1 open-label data readout will also include additional functional measures, reflecting nearly a year of treatment. Cohort 2 data from ELEVATE-44-201 and ELEVATE-45-201 will then further characterize the relationship between dose, exon skipping, dystrophin production and functional outcomes at both higher doses and exposure levels.”

Mr. Doshi continued, “Including the anticipated Phase 1/2 clinical data from our partner Vertex’s GALILEO study in myotonic dystrophy type 1 during the second half of 2026, we expect four clinical data readouts through the first half of 2027. This marks an important period of clinical catalysts for Entrada as we advance our pipeline and work toward our goal of delivering potentially transformative medicines to people living with serious neuromuscular diseases.”

Recent Corporate Highlights

Clinical-Stage Development Pipeline: Entrada continues to advance multiple clinical programs in people living with Duchenne muscular dystrophy (DMD) in the U.K., EU and U.S., complementing the ongoing clinical progress of its myotonic dystrophy type 1 (DM1) partnership (VX-670) with Vertex.

ELEVATE-44-201

• Cohort 1 (6 mg/kg): The Company expects to receive data from the Cohort 1 open-label period of the study by year-end 2026. The open-label period of the study will assess longer-term safety and other functional measures commonly evaluated in DMD clinical studies and will include all participants in the multiple ascending dose (MAD) period who subsequently rolled over to ENTR-601-44. All Cohort 1 participants have received their final dose in the open-label period and rolled into the long-term extension (LTE) study. Previously announced data from the MAD portion of Cohort 1 achieved the primary objective of favorable safety and tolerability, with no discontinuations and no serious adverse events.
• Cohort 2 (12 mg/kg): Enrollment is complete and dosing is ongoing for Cohort 2, with data expected in the first quarter of 2027.
• Cohort 3 (18 mg/kg): In October 2026, the Company announced that an independent Data Monitoring Committee (DMC) reviewed available safety data and recommended initiating Cohort 3 at the highest planned dose, and enrollment is ongoing.
  
  

ELEVATE-44-102: The Company believes this clinical study, in the underserved adult patient population, would best be initiated at the highest advisable starting dose in patients with advanced disease. Following a review of safety, pharmacokinetic and pharmacodynamic data from its lead programs in the U.K. and EU, the Company will continue to engage with the FDA and provide an update on the clinical study design and timing when appropriate.

ELEVATE-45-201

• Cohort 1 (5 mg/kg): In October 2026, the Company reported positive data from Cohort 1 of the global Phase 1/2 MAD clinical study of ENTR-601-45 in ambulatory participants living with DMD who are amenable to exon 45 skipping. Study participants in Cohort 1 received three doses of 5 mg/kg of ENTR-601-45 or placebo. Topline results met the primary objectives of favorable safety and tolerability. Headache was the most common treatment-emergent adverse event (TEAE); one participant experienced two serious TEAEs (vomiting and pyrexia) which subsequently resolved, and there were no study discontinuations. No hypomagnesemia or renal safety concerns were noted and plasma ENTR-601-45 exposures were consistent with those predicted by juvenile non-human primate data. The secondary objectives also met Company expectations. All study participants in Cohort 1 have now progressed to the open-label, Phase 2 portion of the study, where they will receive six doses of 5 mg/kg of ENTR-601-45.
• Cohort 2 (10 mg/kg): Enrollment is complete and dosing is ongoing for Cohort 2, with data expected in the first half of 2027.
• Cohort 3 (up to 15 mg/kg): Data from Cohort 3 to follow pending an independent DMC’s review of all available safety data from Cohort 2 (10 mg/kg), with the potential to recommend initiating Cohort 3 at up to 15 mg/kg.
• In October 2026, the U.S. FDA Office of Orphan Products Development (OOPD) granted orphan drug designation for ENTR-601-45 for the treatment of DMD.
  
  

ELEVATE-LTE

• ELEVATE-44-201 and ELEVATE-45-201 study participants are eligible to participate in a LTE platform study (ENTR-DMD-202) following completion of the open-label dosing period.
• The LTE study protocol, accepted by U.K. and European authorities, enables study participants continued access to ENTR-601-44 and ENTR-601-45 and provides for the collection of longer-term safety and efficacy data, including functional measures.
  
  

ELEVATE-50-201 and ENTR-601-51: The Company expects to submit additional regulatory applications following a review of data from the ongoing studies of its lead programs. The Company is evaluating a variety of options to optimize clinical study execution and expects to provide more specific timeline guidance as the new strategy is finalized.

VX-670: Vertex has completed enrollment and dosing in the MAD portion of the GALILEO global Phase 1/2 clinical trial of VX-670 in people with DM1. The study is assessing both safety and preliminary efficacy, as measured by the change from baseline in the splicing index on muscle biopsy as well as other endpoints, including those that evaluate muscle function and strength, such as video hand opening time (vHOT) and quantitative muscle testing (QMT) score. Vertex is on track to share interim results from the GALILEO study in the second half of 2026.

Expanding Preclinical Pipeline: The Company has generated compelling preclinical data from programs focused on ocular and metabolic diseases. The pipeline includes the advancement of two novel oligonucleotide-based programs for the potential treatment of inherited retinal diseases, where there exists high unmet need. The Company announced its first ocular candidate, ENTR-801, for the potential treatment of Usher syndrome type 2A (USH2A) and plans to nominate a second clinical candidate for an ocular disease by year-end 2026.

Upcoming Investor Conferences

• Guggenheim Healthcare Innovation Conference, Boston, MA on November 9, 2026
• Evercore Healthcare Conference, Miami, FL on December 1, 2026
  
  

Third Quarter 2026 Financial Results

Cash Position: Cash, cash equivalents and marketable securities were $193.0 million as of September 30, 2026, compared to $295.7 million as of December 31, 2025. The decrease was primarily driven by cash used to fund operations. Based on current operating plans, the Company believes that its cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund its operations into the fourth quarter of 2027.

Collaboration Revenue: Collaboration revenue was $0.9 million for the third quarter of 2026, compared to $1.6 million for the same period in 2025.

Research & Development (R&D) Expenses: R&D expenses were $32.4 million for the third quarter of 2026, compared to $38.4 million for the same period in 2025. The decrease was primarily driven by lower preclinical costs for the Company’s Duchenne programs and lower facility-related costs.

General & Administrative (G&A) Expenses: G&A expenses were $10.2 million for the third quarter of 2026, compared to $10.3 million for the same period in 2025. The decrease was primarily driven by lower professional services costs.

Net Loss: Net loss was $39.7 million for the third quarter of 2026, compared to $44.1 million for the same period in 2025.

Patients and Their Care Partners
Patients and their care partners are a critical part of our community, and we are committed to keeping them informed and connected. To receive community updates in real time and read today’s quarterly update, please visit Community Updates on our corporate website.

About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

Forward-Looking Statements
This press release contains express and implied forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Entrada’s strategy, future operations, prospects and plans, objectives of management, the validation and differentiation of Entrada’s approach and EEV platform and its ability to provide a potential treatment for patients, the timing and achievement of anticipated clinical, regulatory and development milestones, expectations regarding Entrada’s Phase 1/2 MAD clinical study of ENTR-601-44, including the potential of the open-label period of the study to assess longer-term safety and other functional measures commonly evaluated in DMD clinical studies, the potential and ability of the LTE study to enable continued access to ENTR-601-44 and ENTR-601-45 for study participants and provide for the collection of longer-term safety and efficacy data, including functional measures, the ability of the ELEVATE-44-201 Cohort 1 open-label data to provide important insights into the underlying biology and the durability of the early functional improvements observed to date, the timing of data from the Cohort 1 open-label period by year-end 2026 and Cohort 2 in the first quarter of 2027 with data from Cohort 3 to follow, expectations regarding the initiation of the planned ELEVATE-44-102 study in the U.S., including Entrada continuing to engage with the FDA and providing an update on the clinical study design and timing when appropriate, the ability to recruit for and complete the global Phase 1/2 clinical studies of ENTR-601-44, ENTR-601-45, ENTR-601-50 and ENTR-601-51, the potential therapeutic benefits of Entrada’s EEV product candidates, including the potential for Entrada’s programs to bring transformative treatment options to people living with serious neuromuscular diseases, expectations regarding Entrada's Phase 1/2 MAD clinical study of ENTR-601-45, including the timing of data from Cohort 2 in the first half of 2027, with Cohort 3 to follow pending an independent DMC’s review of Cohort 2 safety data and the potential to recommend initiating Cohort 3 at up to 15 mg/kg, the ability of the upcoming readouts of ELEVATE-44-201 Cohort 1 open-label data and Cohort 2 data from ELEVATE-44-201 and ELEVATE-45-201 to further define the potential of Entrada’s investigational medicines, the ability of the Cohort 2 readouts from ELEVATE-44-201 and ELEVATE-45-201 to further characterize the relationship between dose, exon skipping, dystrophin production and functional outcomes at higher doses and exposure levels, expectations regarding the submission of regulatory filings of the planned clinical studies of ENTR-601-50 and ENTR-601-51, the ability to advance therapeutic candidates in indications beyond neuromuscular disease, including but not limited to ocular disease, expectations regarding the timing of nomination of a second clinical candidate for ocular disease by year-end 2026, and the continued development and advancement of ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51 for the treatment of DMD and ENTR-801 for the potential treatment of USH2A and the partnered product candidate VX-670 for the potential treatment of DM1, expectations regarding the progress and success of Entrada’s collaboration with Vertex, including the timing of Vertex sharing interim results from the MAD portion of the global Phase 1/2 study of the VX-670 program during the second half of 2026, the ability to continue to expand and develop additional therapeutic programs and modalities, including further exon skipping programs, and the sufficiency of its cash resources into the fourth quarter of 2027, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Entrada may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical studies; uncertainties as to the availability and timing of results from preclinical and clinical studies; the timing of and Entrada’s ability to submit and obtain regulatory clearance and initiate clinical studies; whether results from preclinical studies or clinical studies will be predictive of the results of later preclinical studies and clinical studies; whether Entrada’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Entrada’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-K and in subsequent filings Entrada may make with the SEC. In addition, the forward-looking statements included in this press release represent Entrada’s views as of the date of this press release. Entrada anticipates that subsequent events and developments will cause its views to change. However, while Entrada may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Entrada’s views as of any date subsequent to the date of this press release.

ENTRADA THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations (Unaudited)
(In thousands, except share and per share amounts)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Collaboration revenue	$	905			$	1,614			$	2,678			$	24,122
Operating expenses:
Research and development		32,369				38,361				100,792				108,312
General and administrative		10,225				10,304				30,841				31,500
Total operating expenses		42,594				48,665				131,633				139,812
Loss from operations		(41,689	)			(47,051	)			(128,955	)			(115,690	)
Other income:
Interest and other income		1,974				3,571				6,833				11,936
Total other income		1,974				3,571				6,833				11,936
Loss before provision for income taxes		(39,715	)			(43,480	)			(122,122	)			(103,754	)
Provision for income taxes		27				654				100				832
Net loss	$	(39,742	)		$	(44,134	)		$	(122,222	)		$	(104,586	)
Net loss per share, basic and diluted	$	(0.94	)		$	(1.06	)		$	(2.90	)		$	(2.53	)
Weighted-average common shares outstanding, basic and diluted		42,373,345				41,462,567				42,145,729				41,293,108

ENTRADA THERAPEUTICS, INC.
Condensed Consolidated Balance Sheet Data (Unaudited)
(In thousands)
	September 30,			December 31,
		2026			2025
Cash, cash equivalents and marketable securities	$	193,015		$	295,698
Total assets	$	266,880		$	377,378
Total liabilities	$	68,555		$	71,245
Total stockholders’ equity	$	198,325		$	306,133

Investor Contact
Doug Snow
Head of Investor Relations
dsnow@entradatx.com

Patient Advocacy Contact
Sarah Friedhoff
Head of Patient Advocacy
patientadvocacy@entradatx.com

Media Contact
Megan Prock McGrath
CTD Comms, LLC
megan@ctdcomms.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Entrada Therapeutics’ third-quarter 2026 financial results?

Entrada reported a $39.7 million net loss and $0.9 million in collaboration revenue for the third quarter of 2026. A year earlier, net loss was $44.1 million and collaboration revenue was $1.6 million. Basic and diluted loss per share narrowed to $0.94 from $1.06.

When does TRDA expect its next Duchenne trial results?

Entrada expects ELEVATE-44-201 Cohort 1 open-label data by year-end 2026, Cohort 2 data in the first quarter of 2027, and ELEVATE-45-201 Cohort 2 data in the first half of 2027.

What will Entrada’s ELEVATE-44-201 open-label readout measure?

The readout will assess longer-term safety and functional measures in participants who rolled over from Cohort 1’s multiple ascending dose period to ENTR-601-44. Entrada expects additional functional measures reflecting nearly a year of treatment, including insights into the durability of early functional improvements.

What endpoints is Vertex studying in the VX-670 GALILEO trial partnered with Entrada?

GALILEO assesses safety and preliminary efficacy, including change from baseline in a muscle-biopsy splicing index. Other endpoints evaluate muscle function and strength through video hand opening time and quantitative muscle testing scores.